

New perspective: Evaluation of mucormycosis cases with European QUALity (EQUAL) score

Süheyla Kömür, Ayşe Seza İnal, Aslıhan Ulu, Ferit Kuşcu, Behice Kurtaran, Muhammed Dağkiran, Aysun Uğuz, Yeşim Taşova
Cukurova University, Faculty of Medicine, Adana, Turkey

Background: Mucormycosis is a life-threatening disease especially in patients with hematological malignancies. Excellence Centre for Medical Mycology developed a score to quantify guideline adherence, called EQUAL score for patients with mucormycosis. We aimed to evaluate our patients according to this score for detection the adherence to current guideline recommendations.

Materials-methods: We evaluated our nine patients respectively using the EQUAL Mucormycosis Score developed by Koehler et al in 2018. The records of patients were reviewed retrospectively and 18 item for each patient were measured.

Results: Nine patients from Cukurova University were included. Of those six patients had acute myeloid disease, two had acute lymphoblastic leukemia, one patient had chronic lymphocytic leukemia. The mean age was 43 (18-78) years. Four patients died and the mean of their score was 12.5 (9-18). The others were recovered and their mean score was 22.6(18-25). The EQUAL score was higher in patients with good prognosis. (Table 1)

Table 1. The EQUAL score of each patient

Patient	Sex	Underlying condition	Age	Diagnosis					Treatment			Follow-up	Total	Outcome
1	M	AML	58	3	3	0	2	0	3	3	0	4	18	died
2	M	AML	32	0	3	2	2	0	0	3	0	4	14	died
3	F	AML	66	0	0	0	2	0	2	3	0	2	9	died
4	M	ALL	18	3	3	2	2	0	3	3	2	4	22	survived
5	M	KLL	78	3	3	3	2	0	3	3	2	6	25	survived
6	F	AML	45	3	3	2	2	0	3	3	2	6	24	survived
7	M	ALL	19	3	3	0	2	0	3	3	2	2	18	durvived
8	F	AML	25	3	3	2	2	0	3	3	2	6	24	survived
9	M	AML	54	0	0	0	2	0	2	3	0	2	9	died

Conclusions: The EQUAL mucormycosis score may be a good predictor of prognosis. It may be be usefull for monitoring patients.